Document
OZEMPIC, 209637, Letter (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Letter (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Label (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Label (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Review Approval Letters (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Review Approval Letters (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Review Statistical Reviews (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Review Statistical Reviews (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Review Summary Review (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Review Summary Review (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Review Pharmacology Reviews (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Review Pharmacology Reviews (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Review Other Reviews (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Review Other Reviews (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Review Printed Labeling (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Review Printed Labeling (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Review Administrative Documents & Correspondence (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Review Administrative Documents & Correspondence (Orange Book Dec. 5, 2017)
+ More Snippets
Document
OZEMPIC, 209637, Review Clinical Pharmacology Biopharmaceutics Reviews (Orange Book Dec. 5, 2017)
Cite Document
OZEMPIC, 209637, Review Clinical Pharmacology Biopharmaceutics Reviews (Orange Book Dec. 5, 2017)
+ More Snippets
Document
IPR2024-00631, No. 1062 Exhibit - 1062 Zarin, The ClinicalTrialsgov Results Database—Update and Key Issues, (P.T.A.B. Mar. 1, 2024)
Cite Document
IPR2024-00631, No. 1062 Exhibit - 1062 Zarin, The ClinicalTrialsgov Results Database—Update and Key Issues, (P.T.A.B. Mar. 1, 2024)
+ More Snippets
Document
IPR2024-00631, No. 1012 Exhibit - 1012 Lovshin, Incretin Based Therapies for Type 2 Diabetes Mellitus, 5 NATU (P.T.A.B. Mar. 1, 2024)
Cite Document
IPR2024-00631, No. 1012 Exhibit - 1012 Lovshin, Incretin Based Therapies for Type 2 Diabetes Mellitus, 5 NATU (P.T.A.B. Mar. 1, 2024)
+ More Snippets
Document
IPR2024-00631, No. 1506 Exhibit - 1506 CV of Hugh DC Smyth, PhD (P.T.A.B. Mar. 1, 2024)
Cite Document
IPR2024-00631, No. 1506 Exhibit - 1506 CV of Hugh DC Smyth, PhD (P.T.A.B. Mar. 1, 2024)
+ More Snippets
Document
IPR2024-00631, No. 1029 Exhibit - 1029 Jimenez Solem, Dulaglutide, a Long Acting GLP1 Analog Fused with an F (P.T.A.B. Mar. 1, 2024)
Cite Document
IPR2024-00631, No. 1029 Exhibit - 1029 Jimenez Solem, Dulaglutide, a Long Acting GLP1 Analog Fused with an F (P.T.A.B. Mar. 1, 2024)
+ More Snippets
Document
IPR2024-00631, No. 1028 Exhibit - 1028 Holst, Glucagon Like Peptide 1 and Inhibitors of Dipeptidyl Peptidase (P.T.A.B. Mar. 1, 2024)
Cite Document
IPR2024-00631, No. 1028 Exhibit - 1028 Holst, Glucagon Like Peptide 1 and Inhibitors of Dipeptidyl Peptidase (P.T.A.B. Mar. 1, 2024)
+ More Snippets